Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Esketamine + morphine sulfate is a combination of two medications with different mechanisms of action. Esketamine is an NMDA receptor antagonist that is the S-enantiomer of ketamine, while morphine sulfate is an opioid analgesic. When combined, these medications may have synergistic analgesic effects. Studies have shown that this combination affects respiratory function, causing displacement of ventilatory response to CO2. Esketamine may have opioid-sparing effects, potentially allowing for reduced morphine dosages while maintaining analgesic efficacy. This combination has been studied for use in pain management and anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on esketamine + morphine sulfate.